Caligan Partners LP holds a focused book of 24 stocks worth $1.4B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Spyre Therapeutics Inc and trimmed Tango Therapeutics Inc. Their largest long position is Liquidia Corp at 22% of the equity book. They also disclosed $88.9M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1727492/holdings"
Use Arkolith to show Caligan Partners LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Liquidia Corporation COM NEW | $306.4M | 8.12M | 21.7% | —Held | |
| 2 | Abivax Sa SPONSORED ADS | $162.8M | 1.46M | 11.5% | ▲+0.7% Added · +10K sh | |
| 3 | Revolution Medicines Inc COM | $160.7M | 1.65M | 11.4% | ▲+29% Added · +369K sh | |
| 4 | Vaxcyte Inc COM | $119.7M | 2.06M | 8.5% | ▲+21% Added · +356K sh | |
| 5 | Xenon Pharmaceuticals Inc COM | $81.0M | 1.39M | 5.7% | ▲+153% Added · +843K sh | |
| 6 | Mineralys Therapeutics Inc COM | $75.1M | 2.77M | 5.3% | —Held | |
| 7 | Exelixis Inc COM | $66.6M | 1.55M | 4.7% | —Held | |
| 8 | Tango Therapeutics Inc COM | $50.4M | 2.41M | 3.6% | ▼−35% Reduced · −1.3M sh | |
| 9 | Tyra Biosciences Inc COM | $48.9M | 1.28M | 3.5% | ▲+35% Added · +333K sh | |
| 10 | Spyre Therapeutics Inc COM NEW | $44.3M | 878.1K | 3.1% | ▲New New position | |
| 11 | Adma Biologics Inc COM | $42.9M | 4.76M | 3.0% | ▲+58% Added · +1.7M sh | |
| 12 | LB Pharmaceuticals Inc COM SHS | $34.6M | 1.44M | 2.4% | ▲New New position | |
| 13 | Vor Biopharma Inc COM NEW | $34.3M | 1.93M | 2.4% | ▲+108% Added · +1000K sh | |
| 14 | SAB Biotherapeutics Inc COM NEW | $30.5M | 7.97M | 2.2% | ▲New New position | |
| 15 | Opus Genetics Inc COM | $27.6M | 6.08M | 2.0% | ▲New New position | |
| 16 | Inventiva Sa ADS | $27.6M | 4.97M | 2.0% | ▲+149% Added · +3.0M sh | |
| 17 | MBX Biosciences Inc COM | $25.3M | 848.6K | 1.8% | ▲New New position | |
| 18 | Avalo Therapeutics Inc COM NEW | $24.4M | 1.64M | 1.7% | ▲+85% Added · +753K sh | |
| 19 | Anika Therapeutics Inc COM | $20.8M | 1.44M | 1.5% | —Held | |
| 20 | Maze Therapeutics Inc COM | $18.4M | 615.0K | 1.3% | ▲+12% Added · +65K sh | |
| 21 | Verrica Pharmaceuticals Inc COM SHS | $4.9M | 923.9K | 0.3% | —Held | |
| 22 | Sensei Biotherapeutics Inc COM NEW | $4.0M | 126.0K | 0.3% | ▲New New position | |
| 23 | Aura Biosciences Inc COM | $1.5M | 229.9K | 0.1% | ▲New New position | |
| 24 | Xilio Therapeutics Inc COM | $943K | 112.1K | 0.1% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | CG ONCOLOGY INCCGON | $60.9M | 900K |
| CALL · bullish | REVOLUTION MEDICINES INCRVMD | $22.3M | 229K |
| CALL · bullish | AGIOS PHARMACEUTICALS INCAGIO | $3.0M | 90K |
| CALL · bullish | ADMA BIOLOGICS INCADMA | $2.7M | 300K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.